NMTC NEUROONE MED TECHNOLOGIES CO revenue, earnings and financials
For the quarter ended June 30, 2026, NEUROONE MED TECHNOLOGIES CO reported revenue of $1.97M (up 16.3% from a year earlier), net income of −$2.01M and diluted EPS of −$0.28; over the last four quarters revenue was $9.47M and net income −$7.45M; for the fiscal year ended September 2025 revenue was $9.10M, up 163.5% on the year before.
NMTC annual revenue and earnings
- Fiscal year ended Sep 2025: revenue $9.10M, gross profit $5.14M, operating income −$4.23M, net income −$3.61M (margin -39.6%), EPS −$0.09
- Fiscal year ended Sep 2024: revenue $3.45M, gross profit $1.08M, operating income −$11.9M, net income −$12.3M (margin -356.7%), EPS −$0.46
- Fiscal year ended Sep 2023: revenue $1.95M, gross profit $457K, operating income −$12.0M, net income −$11.9M (margin -607.4%), EPS −$0.65
- Fiscal year ended Sep 2022: revenue $171K, gross profit −$70.8K, operating income −$10.0M, net income −$10.00M (margin -5842.0%), EPS −$0.63
- Fiscal year ended Sep 2021: revenue $178K, gross profit −$97.7K, operating income −$10.2M, net income −$9.95M (margin -5584.3%), EPS −$0.93
NMTC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.97M (up 16.3% year over year), net income −$2.01M, EPS −$0.28
- Quarter ended Mar 31, 2026: revenue $1.86M (up 34.3% year over year), net income −$2.38M, EPS −$0.28
- Quarter ended Dec 31, 2025: revenue $2.89M (down 11.7% year over year), net income −$1.44M, EPS −$0.03
- Quarter ended Sep 30, 2025 (from the annual report): revenue $2.74M (up 906.6% year over year), net income −$1.62M, EPS $0.48
- Quarter ended Jun 30, 2025: revenue $1.70M (up 105.4% year over year), net income −$1.50M, EPS −$0.19
- Quarter ended Mar 31, 2025: revenue $1.39M (up 0.7% year over year), net income −$2.27M, EPS −$0.44
- Quarter ended Dec 31, 2024: revenue $3.27M (up 234.9% year over year), net income $1.79M, EPS $0.06
- Quarter ended Sep 30, 2024 (from the annual report): revenue $272K (down 63.3% year over year), net income −$3.35M, EPS −$0.11
- Quarter ended Jun 30, 2024: revenue $826K (up 31.1% year over year), net income −$2.77M, EPS −$0.10
- Quarter ended Mar 31, 2024: revenue $1.38M (up 195.4% year over year), net income −$2.86M, EPS −$0.11
- Quarter ended Dec 31, 2023: revenue $978K (up 753.3% year over year), net income −$3.34M, EPS −$0.14
- Quarter ended Sep 30, 2023 (from the annual report): revenue $742K (up 978.4% year over year), net income −$3.14M, EPS −$0.13
- Quarter ended Jun 30, 2023: revenue $630K (up 1865.4% year over year), net income −$3.47M, EPS −$0.20
- Quarter ended Mar 31, 2023: revenue $466K (up 1174.3% year over year), net income −$3.52M, EPS −$0.21
- Quarter ended Dec 31, 2022: revenue $115K (up 239.5% year over year), net income −$1.73M, EPS −$0.11
- Quarter ended Sep 30, 2022 (from the annual report): revenue $68.8K, net income −$1.37M, EPS −$0.09
- Quarter ended Jun 30, 2022: revenue $32.0K (down 20.1% year over year), net income −$2.76M, EPS −$0.17
- Quarter ended Mar 31, 2022: revenue $36.6K (up 100.6% year over year), net income −$3.06M, EPS −$0.19
- Quarter ended Dec 31, 2021: revenue $33.7K, net income −$2.81M, EPS −$0.18
- Quarter ended Jun 30, 2021: revenue $40.1K, net income −$2.95M, EPS −$0.25
NMTC cash flow, buybacks and dividends
- Fiscal year ended Sep 2025: operating cash flow −$2.84M, share buybacks n/a
- Fiscal year ended Sep 2024: operating cash flow −$11.0M, share buybacks n/a
- Fiscal year ended Sep 2023: operating cash flow −$12.9M, share buybacks n/a
- Fiscal year ended Sep 2022: operating cash flow −$7.52M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow −$8.60M, share buybacks n/a
NMTC balance sheet
- Jun 30, 2026: cash $2.05M, total assets $6.19M, total liabilities $2.42M, shareholders' equity $3.77M
- Mar 31, 2026: cash $2.80M, total assets $7.57M, total liabilities $2.49M, shareholders' equity $5.08M
- Dec 31, 2025: cash $3.56M, total assets $8.58M, total liabilities $2.18M, shareholders' equity $6.40M
- Sep 30, 2025: cash $6.57M, total assets $10.8M, total liabilities $3.71M, shareholders' equity $7.07M
- Jun 30, 2025: cash $8.04M, total assets $10.8M, total liabilities $2.64M, shareholders' equity $8.18M
- Mar 31, 2025: cash $1.32M, total assets $4.46M, total liabilities $3.33M, shareholders' equity $1.13M
- Dec 31, 2024: cash $1.13M, total assets $6.49M, total liabilities $3.56M, shareholders' equity $2.94M
- Sep 30, 2024: cash $1.46M, total assets $5.37M, total liabilities $4.55M, shareholders' equity $822K
What is NMTC's revenue?
NEUROONE MED TECHNOLOGIES CO reported $9.47M of revenue over its last four quarters, through June 30, 2026.
Is NMTC profitable?
No. NEUROONE MED TECHNOLOGIES CO lost $7.45M over the last four quarters.
What is NMTC's EPS?
Diluted earnings per share over the last four quarters were −$0.11; −$0.28 in the latest quarter.